Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia

British Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2011, Pages 514-521

  Bogason, Alex ^a   Quartino, Angelica L ^b   Lafolie, Pierre ^a   Masquelier, Michèle ^a   Karlsson, Mats O ^b   Paul, Christer ^a   Gruber, Astrid ^a   Vitols, Sigurd ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acute myeloid leukaemia; Anthracycline; Daunorubicin; Pharmacokinetics; Plasma; Tumour burden

Indexed keywords

CYTARABINE; DAUNORUBICIN; DAUNORUBICINOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ISOLATION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CLEARANCE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; DAUNORUBICIN; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; MALE; MIDDLE AGED; MODELS, THEORETICAL; REGRESSION ANALYSIS;

EID: 79952600762     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03894.x     Document Type: Article

References (26)

1. Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Am J Hematol 2004; 76: 319-29.
2. Palle J, Frost BM, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, Schmiegelow K, Lonnerholm G. Doxorubicin pharmacokinetics are correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 2006; 17: 385-92.
3. Masquelier M, Vitols S. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside. Biochem Pharmacol 2004; 67: 1639-46.
4. Kobayashi H, Takemura Y, Ohnuma T. Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects. Cancer Chemother Pharmacol 1992; 31: 6-10.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-8.
6. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1g. Scand J Clin Lab Invest Suppl 1968; 97: 77-89.
7. Bogason A, Bhuiyan H, Masquelier M, Paul C, Gruber A, Vitols S. Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response. Eur J Clin Pharmacol 2009; 65: 1179-86.
8. Callies S, de Alwis DP, Mehta A, Burgess M, Aarons L. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother Pharmacol 2004; 54: 39-48.
9. Matthews JP, Bishop JF, Young GA, Juneja SK, Lowenthal RM, Garson OM, Cobcroft RG, Dodds AJ, Enno A, Gillett EA, Hermann RP, Joshua DE, Ma DD, Szer J, Taylor KM, Wolf M, Bradstock KF. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br J Haematol 2001; 113: 727-36.
10. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, Tigaud I, Raffoux E, Rousselot P, Sigaux F, Degos L, Castaigne S, Fenaux P, Dombret H. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-704.
11. Robert J, Rigal-Huguet F, Harousseau JL, Pris J, Huet S, Reiffers J, Hurteloup P, Tamassia V. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Leuk Res 1987; 11: 961-4.
12. DeGregorio MW, Holleran WM, Macher BA, Linker CA, Wilbur JR. Kinetics and sensitivity of daunorubicin in patients with acute leukemia. Cancer Chemother Pharmacol 1984; 13: 230-4.
13. Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit 1989; 11: 140-8.
14. Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Lonnerholm G. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 2002; 38: 329-37.
15. Preisler HD, Gessner T, Azarnia N, Bolanowska W, Epstein J, Early AP, D'Arrigo P, Vogler R, Winton L, Chervenik P. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1984; 12: 125-30.
16. Kokenberg E, Sonneveld P, Sizoo W, Hagenbeek A, Lowenberg B. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol 1988; 6: 802-12.
17. Paul C, Tidefelt U, Liliemark J, Peterson C. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time. Leuk Res 1989; 13: 191-6.
18. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72h infusion. Cancer Chemother Pharmacol 1987; 20: 311-5.
19. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41: 431-44.
20. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 1989; 45: 340-7.
21. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993; 53: 555-61.
22. Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it. Int J Hematol 2000; 72: 418-24.
23. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Mollgard L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000; 18: 1837-44.
24. Kokenberg E, van der Steuijt K, Lowenberg B, Nooter K, Sonneveld P. Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. Haematol Blood Transfus 1987; 30: 283-7.
25. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Dohner H, Gratwohl A, Pabst T, Verhoef G. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-48.
26. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-59.